Stay updated with breaking news from Hooman Kamel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In patients with cryptogenic stroke and evidence of atrial cardiopathy without atrial fibrillation, apixaban did not reduce recurrent stroke vs aspirin in the ARCADIA trial.
For patients with recent cryptogenic stroke and evidence of atrial cardiopathy, the risk for recurrent stroke is not reduced with apixaban.
No significant difference noted in recurrent stroke, symptomatic intracranial hemorrhage for patients receiving apixaban, aspirin.
A multicenter, phase 3 clinical trial has found that apixaban is no more effective than aspirin at preventing a second stroke in patients diagnosed with a milder, related condition called atrial cardiopathy, according to new research.
Anticoagulation and antiplatelet therapy show no significant difference in recurrent stroke risk among patients with cryptogenic stroke and evidence of atrial cardiopathy.